# US 2026/0096997 A1 · Delivery system comprising silicon nanoparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0096997 A1
- Document ID: US20260096997A1
- Status: Published application
- Kind: A1
- Application number: 19/381,591
- Filed: 2025-11-06
- Published: 2026-04-09
- Earliest claimed: 2019-03-28
- Assignees: Sisaf Limited
- Applicants: Sisaf Limited
- Inventors: Roghieh Suzanne SAFFIE-SIEBERT; Paulina Malgorzata BARAN-RACHWALSKA; Flavia Maria SUTERA; Nasrollah TORABI-POUR
- Web page: https://patentgrep.com/patent/US20260096997A1

## CPC

- A61K 9/5115: {Inorganic compounds}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 27/02: Ophthalmic agents
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A composition for the controlled release of a nucleic acid such as short interfering RNA or messenger RNA, comprising silicon nanoparticles, at least one amino acid, and at least one lipid, wherein the silicon nanoparticles comprise at least 50% by weight silicon. Also related compositions and methods.

## Claims

### Claim at position 1

-18. (canceled)

### Claim 19

A composition for the controlled release and stabilization of a nucleic acid molecule, comprising silicon nanoparticles which comprise at least 50% by weight silicon, wherein the silicon nanoparticles are surface treated with at least one lipid and at least one amino acid, wherein the surface treated silicon nanoparticles are loaded with the nucleic acid, wherein the ratio of silicon to nucleic acid is from 2:1 to 8:1, wherein, upon administration to eukaryotic cells, the nucleic is transfected into the eukaryotic cells.

### Claim 20 (depends on 19)

The composition according to claim 19, wherein the nucleic acid is short interfering RNA.

### Claim 21 (depends on 19)

The composition according to claim 19, wherein the nucleic acid is messenger RNA.

### Claim 22 (depends on 19)

The composition according to claim 19, wherein the ratio of silicon to nucleic acid is from 2:1 to 3:1.

### Claim 23 (depends on 19)

The composition according to claim 19, further comprising at least one disaccharide.

### Claim 24 (depends on 19)

The composition according to claim 19, wherein the at least one lipid comprises a cationic lipid.

### Claim 25 (depends on 24)

The composition according to claim 24, wherein the cationic lipid is selected from the group consisting of Cholesteryl N-(2-dimethylaminoethyl)carbamate, stearylamine, and combinations thereof.

### Claim 26 (depends on 24)

The composition according to claim 24, wherein the cationic lipid is selected from the group consisting of Cholesteryl N-(2-dimethylaminoethyl)carbamate, stearylamine, and combinations thereof, and wherein the silicon nanoparticle is further surface treated with at least one lipid is selected from the group consisting of phosphatidylcholine, hydrogenated phosphatidylcholine, phosphatidylcholine derivatives, didecanoyl phosphatidylcholine, lecithin, phosphatidylethanolamine, 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine, and combinations thereof.

### Claim 27 (depends on 19)

The composition according to claim 19, wherein the at least one lipid is selected from the group consisting of phosphatidylcholine, hydrogenated phosphatidylcholine, phosphatidylcholine derivatives, didecanoyl phosphatidylcholine, lecithin, phosphatidylethanolamine, 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine, and combinations thereof.

### Claim 28 (depends on 19)

The composition according to claim 19, wherein the ratio of amino acid to silicon is from 0.05:1 to 2:1.

### Claim 29 (depends on 19)

The composition according to claim 19, wherein the silicon nanoparticles have an average diameter of between 20 and 200 nm.

### Claim 30 (depends on 19)

A composition according to claim 19, wherein the at least one amino acid is selected from arginine, glycine, histidine or combinations thereof.

### Claim 31 (depends on 19)

A pharmaceutical composition for controlled release of messenger RNA, comprising the composition of claim 19.

### Claim 32 (depends on 19)

A method comprising administering the composition of claim 19 to a subject.

### Claim 33 (depends on 32)

The method of claim 32, wherein the composition is administered by ophthalmic delivery.

### Claim 34 (depends on 19)

A method of preparing the composition of claim 19, comprising:
(a) providing silicon nanoparticles, wherein the silicon nanoparticles comprise at least 50% by weight silicon, wherein the silicon nanoparticles are surface treated with at least one lipid, and further treated with at least one amino acid; a nucleic acid molecule; and
(b) loading the nucleic acid molecule on the silicon nanoparticles.
